Objectives: The guidelines of American Thyroid Association (ATA) 2011 recommends in hypothyroid women receiving levothyroxine (LT4) and in untreated women with subclinical hypothyroidism and/or positive TPOAb (antibodies against thyroid peroxidase) regular laboratory check-up every 4 weeks during the 1st half of pregnancy and at least once between 26th-32th weeks of gravidity. Our aim was to verify whether thyroid check-up between 26th-32thgestation weeks is beneficial in terms of LT4 dosage changes. MethOds: We performed a retrospective cross-sectional study in [2004][2005][2006][2007][2008][2009][2010][2011][2012][2013][2014] in the Departments of Endocrinology of a university hospital and with laboratory assessment in a single center. The study included 188 women positively screened for hypothyroidism and/or positive TPOAb in first trimester of pregnancy. They were followed and examined according to the recommended algorithm by ATA 2011. We assessed serum concentrations of TSH, FT4 and TPOAb and evaluated changes of LT4 dosage with regard to week of laboratory check-up. Finally, we calculated direct medical costs per LT4 dosage change. Results: Of the 188 positively screened women in the first trimester, 104 (55.3%) were hypothyroid and 84 (44.7%) were euthyroid but TPOAb positive. Overall, 104 women (55.3%) undergo three laboratory check-ups, 57 (30.3%) four check-ups and 27(14.4%) five check-ups. The median entrance dose of LT4 was 50ug/day (range 0 -170ug/day). The Laboratory check-up between 26th-32th gestation weeks led to LT4 dosage change in 18/132 (13.6%) women comparison to 131/167 (35.7%) in 10th week, 55/142 (38.7%) in 14th week and 43/165 (26.1%) in 20th gestation weeks (p< 0.001). Average costs per LT4 dose change per women were 34.71EUR in 10th week, 47.01EUR in 14th week, 65.01EUR in 20th week and 127.53EUR in 30thgesta-tion weeks. cOnclusiOns: Thyroid check-up between 26th-32th gestation weeks in women with hypothyroidism and/or positive TPOAb seems to be redundant in terms of LT4 dosage changes and produces inadequate high costs.
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PIH21 mOdellIng tHe COSt determInantS fOr Older PerSOnS' tranSItIOnS In Care (OPtIC)
Kudinga BM, McCabe C, Cummings G University of Alberta, Edmonton, AB, Canada Objectives: The transfers of nursing home (NH) residents to the emergency departments (ED) is costly for the healthcare systems. In this regard, the cost-analysis can be a useful tool to provide evidence-based information to guide resource allocation. In this study, we analyze the cost at different stages of the transitions for Edmonton, Alberta, in Canada and evaluate the extent to which nursing home attributes, patients' characteristics, and the transfers' outcomes are significantly associated with the transfers cost. MethOds: We used a representative data collected in 2011 from 398 residents and 28 nursing homes in Edmonton, Alberta from multiple levels and sources (facility, residents, healthcare providers, health records, administrative databases, etc.). We conducted a preliminary study to describe the costs at different stages of the transitions. Statistical modeling was used to identify any significant predictors of the transfers cost and estimate the magnitude of their impact. We investigated the ordinary least squares (OLS) models, the GLM, and the mixed effects regression models for clustered data. Models are assessed based on standard goodness-of-fit tests. Results: We find that hospitalization represents 48% of the transfers total cost, whilst the emergency-department nursing cost and the nursing-home cost account for 26% and 10% respectively. The emergencyMedical-Services account for 10%, and the diagnostic cost represents 3%. The physicians plus consultations and the treatment costs represent 2% each. The estimation results show that sociodemographic factors, health characteristics, communication of information, healthcare providers' involvement in the decision, the nature of the transfer coordinator, and providing medical care in the nursing home are significant predictors of the transfers cost. cOnclusiOns: The results of this analysis may fit into a subsequent cost-effectiveness analysis for the transfers cost. Objectives: Genotyping for the cytochrome P450-2D6 has the potency to predict differences in metabolism of nortriptyline. This information could optimize treatment. We explored if possible benefits could outweigh genotyping costs for Dutch depressed patients in clinical psychiatry. MethOds: First, a decision-tree was created to model the first weeks of nortriptyline therapy. In the model, costs of hospitalization, therapeutic drug monitoring, and drug costs were captured. Based on the patients genetics, patients were distributed among three health states: correctly, sub-, or supra-therapeutically dosed. Utilities for each of these health states and at different points in time were obtained from an expert opinion (nine clinicians). Second, an improvement in sub or supra-therapeutically dosed patients to correctly dosed patients, was simulated, assuming genotyping would prevent under or overdosing. In the base case the improvement was 36%. In addition, we assumed genotyping could reduce hospitalization days with a maximum of 3.7 days (average: 28.6 days). Results from the model without genotyping were compared with the genotyping model. In a scenario analyses we varied the effects of genotyping to reach cost-effectiveness at € 20 000/quality adjusted life year (QALY) or € 50 000/ QALY. In a univariate sensitivity analysis, effects of lowering genotyping costs were examined. A probabilistic sensitivity analysis (PSA) was performed to investigate influence of parameter uncertainty. Results: In the base case, the incremental cost-effectiveness ratio (ICER) was € 32 697/QALY. For an ICER of € 20 000/QALY, a genotyping facilitated improvement of 45% was needed and for € 50 000/QALY this was 27%. Lowering the genotype price to € 162 made genotyping cost-saving. Results of the PSA indicated a probability of 0.95 for a willingness-to-pay threshold of € 46000/ QALY. cOnclusiOns: Genotyping could be cost-effective and even be cost-saving when genotyping costs drops. However, there is a need for more clinical evidence to support assumptions made in this model. Objectives: The purpose of this study was to develop the econometric model predicting the non-prescription medicines expenditure at community pharmacies in Malaysia MethOds: This study used data from 2009 Non-Prescription Medicines Utilization among Community Pharmacy Patrons in Malaysia (COMPACT1) and Sales of Non-Prescription Medicine in Community Pharmacy Malaysia (COMPACT2). The prices of non prescription medicines (NPM) in 2009 were updated to prices of 2014, based on Malaysian Consumer Price Index. There were four major components in the empirical model namely; socio-economic characteristics, health status, utilization behavior and community pharmacy data. The dependent variable was the logarithm function of expenditure for purchasing the NPM. Ordinary least square method on cross-sectional data was used to predict model of NPM among community pharmacy patrons. Results: Twenty two percent (22.3%) of variation in NPM expenditure was explained by socio-economic characteristics, health status, utilization behavior, and community pharmacy data. Age, female, living at urban area, and had monthly household income more than RM3000 per month (~USD850) were found to have linear positive relationship with money spent. Those customers who had problem in pain or discomfort had 0.059 units lesser in expenditure of NPM. Number of medicines purchased, satisfaction towards price, usage frequency of medicines, and the ways of product selection were among variables in utilization behavior that had significant linear relationship with NPM. The community pharmacy data on the working days and percentage of customers purchasing over total customers in a month shows significant negative linear relationship with NPM expenditure. cOnclusiOns: The study had given additional insight on the economics of self-medication and the role of community pharmacy as supplier of health care. The expenditure of NPM in Malaysia can be explained by empirical model that includes the purchasers' socio-economic characteristic, health status, NPM utilization behavior and the information regarding utilization of community pharmacy. Objectives: The medication adherence of patients using widely prescribed beta blockers (Atenolol and Metoprolol) in their extended and immediate release salt form remains unidentified. Improving medication adherence has been shown to reduce health care costs. Analyzing the treatment having maximum medication adherence could reduce overall healthcare costs, offsetting the cost of the medication itself. The objectives of this study are to 1) compare the medication adherence of patients prescribed with Atenolol and Metoprolol in both immediate and extended release forms 2) determine the difference in healthcare expenditure between those highly adherent to the beta-blockers under study. MethOds: Secondary data analysis using the Medical Expenditure Panel Survey (MEPS) conducted by the Agency for Healthcare Research and Quality and the National Center for Health Statistics. Medication Possession Ratio (MPR) will be used to calculate the medication adherence. Patients will then be divided into three categories: high adherence (80-100%), intermediate adherence (79%-60%), and low adherence (< 60%). Healthcare expenditure will be analyzed for each medication. Healthcare expenditures will then be compared between those who are highly adherent to each medication. Healthcare costs analyzed will include ER, outpatient, inpatient visits and prescription medication payments. Results: The patients with Atenolol extended release were associated with the lowest adherence. Patients with Metoprolol treatment were more adherent than those taking Atenolol (p< 0.0001). Also, within the extended release group, Metoprolol Succinate had a greater rate of high adherence than Atenolol (p< 0.001). For patients with high medication adherence, the expenditure was the lowest for Metoprolol Succinate ($12490.33). Also, for immediate release, Metoprolol Tartrate has significantly lower healthcare costs. cOnclusiOns: Metoprolol is associated with higher adherence than atenolol. Also, the healthcare expenditure for Metoprolol is significantly lower than Atenolol.
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PIH25 a SyStematIC revIeW Of tHe USe Of tHe tIme PreferenCe mOdel tO exPlOre medICatIOn adHerenCe BeHavIOr
Mezgebe M, Lovett AW Mercer University, Atlanta, GA, USA Objectives: Non-adherence to prescription medication has a significant impact on a patient's health; often causing poorer health outcomes, preventable mortality and unnecessary utilization of healthcare services. Previous literature has been inconsistent as to what factors affect a patients' adherence to prescription medication. Time preference, the extent that individuals are willing to discount future benefits for immediate benefits, has recently been acknowledged as a framework
